Insilico Medicine Secures Multi-Million-Dollar AI Collaboration to Build and Commercialize Biology Foundation Models

Stock News
09/21

Insilico Medicine (03696) has announced a new partnership with a leading foundation model laboratory, securing a collaboration contract valued at up to tens of millions of dollars. The agreement focuses on co-developing, validating, and commercializing a suite of advanced foundation models designed specifically for biological research, leveraging the MMAI Gym training framework.

Under the terms of the deal, both parties will integrate their respective strengths to construct specialized foundation models tailored for generative biology. Insilico Medicine will contribute proprietary datasets covering a range of specialized life science tasks and will conduct closed-loop wet-lab validation on the outputs generated by these foundation models during their training phase.

Furthermore, the collaboration establishes a revenue-sharing model designed to drive global commercialization efforts by tapping into each partner's extensive networks within the biopharmaceutical industry. This strategic alliance underscores a shared commitment to accelerating innovation at the intersection of artificial intelligence and life sciences.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10